News

Dividends can provide a steady stream of income to shareholders, but only if the dividend-paying company maintains or increases its payouts over the years. Unfortunately, not every dividend payer is

The past nine months have been rough ones to be an Agenus (NASDAQ: AGEN) shareholder. The stock has collapsed by about 75% from the peak it set last June.

Investment bank analysts on Wall Street who

Microsoft (NASDAQ: MSFT) is currently the only company worth over $3 trillion. That makes it the most heavily weighted stock in both the S&P 500 and the Nasdaq Composite, but not the Dow Jones

Cybersecurity has been one of the hottest investment sectors in recent years. Given the number of high-profile cybersecurity attacks and breaches, this probably should not be surprising. For

The biotech industry can be attractive for several reasons. Many leading biotechs develop innovative, life-saving therapies, a business that will only be phased out once we find an all-purpose cure

One of the hottest areas of the pharmaceutical industry right now is the weight loss treatment space. Novo Nordisk and Eli Lilly have been the primary innovators. Their groundbreaking glucagon-like

Three Motley Fool contributors have dividends on their minds as the second quarter of 2024 begins. And they think they've found some no-brainer dividend stocks to buy in April. Here's why they like

While no one can say with absolute certainty what the market will or won't do in 2024, finding great stocks that have the power to stand the test of time in your portfolio doesn't have to be

Shares of Humana (NYSE: HUM) are down 11.8% so far this week as of Thursday's close, according to data provided by S&P Global Market Intelligence, after the U.S. Centers for Medicare and Medicaid

Madrigal Pharmaceuticals (NASDAQ: MDGL) and Viking Therapeutics (NASDAQ: VKTX) are both biotechs developing treatments for metabolic diseases, so it's to be expected that they have more than a few

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) has been on fire over the past three years. The company has delivered solid clinical progress and an important regulatory approval, and its

Are we witnessing the rise of a new biotech giant? A few weeks ago, Viking Therapeutics (NASDAQ: VKTX) grabbed headlines when it reported positive results from a phase 2 clinical trial for VK2735, a

Viking Therapeutics (NASDAQ: VKTX) is on a tear this year, with shares catapulting upward by 340% thanks to good data (and high expectations) from one of its mid-stage clinical trials testing a

What's the most important ingredient for investing successfully? Time. However, some stocks require much less time to deliver huge returns than others.

You may have to be patient for significant

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have seen their revenue soar in recent times thanks to their weight loss drugs. The companies sell products that target key hormones involved in

Any one-product company that receives good news about that product will likely attract investors. That was the case Wednesday with Amarin (NASDAQ: AMRN), which received very encouraging news about

Shares of several leading health insurance managed care stocks plunged today after the federally run Centers for Medicare and Medicaid Services (CMS) finalized a lower-than-expected 3.7% payment

Sometimes it is worth it to buy shares of companies on the dip, and sometimes it isn't. It all depends on whether there are good reasons to believe the company in question will bounce back, and if

Cyberattacks can disrupt corporations, and you've seen that play out in recent weeks. UnitedHealth Group (NYSE: UNH) fell roughly $14 billion behind in paying claims after a hacker group attacked